Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. READ MORE
This post is part of the Epilepsy Blog Relay. This blog post was submitted by Sunovion Pharmaceuticals Inc., the Founding Sponsor of the June 2019 Epilepsy … Read More
Mark your calendar for the online event this Saturday May 6, 10am-6pm pst ( 1-9pm est ) , the “TALK ABOUT IT for Epilepsy” Netathon
Sunovion Pharmaceuticals Inc. (Sunovion) announced on August 28, 2015 that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Aptiom® (eslicarbazepine acetate) as monotherapy for the treatment of partial-onset seizures.
